Recommended Stock Newsletters
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

Stockpalooza Newsletter

Time for the ONCS squeeze soon!OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulsehttp://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=g5_NWYP63n35xa35FA9rHA OncoSec Announces Promising Phase 2 Result For Cancer Immunotherapy OncoSec reported positive Phase 2 trial results for its cancer immunotherapy, ImmunoPulse IL-12, in treating patients with metastatic melanoma OncoSec Medical Inc (OTCMKTS:ONCS [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=sCo8LnxZVbmT38KJ3TZ0Ng ]) announced on Friday that its DNA-based cancer immunotherapy, ImmunoPulse IL-12, which is being designed to treat patients with metastatic melanoma, had exhibited promising results in its Phase 2 trials. The top line six months data [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&biSbc8S8cjN5t5koeXmEQ ] from Phase 2 trials, conducted to evaluate the efficacy and safety of the experimental treatment on patients with stage 3 and 4 metastatic melanoma, was reported by Dr. Robert H. Pierce, OncoSec`s chief scientific officer, at the Melanoma Bridge 2014 conference in Italy.

The positive results from 30 patients include: 31% best overall response rate (bORR) and 14% complete response rate as measured by Response Evaluation Criteria In Solid Tumors (RECIST) in patients with metastatic melanoma who were given the experimental drug. RECIST is a set of published rules that define when cancer patients improve (respond), stay the same (stable) or worsen (progression) during treatments.

The company [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&biSbc8S8cjN5t5koeXmEQ ] also announced that the analysis of long-term survival results of Phase 1 study, which evaluated ImmunoPulse LI-12s efficacy in treating patients with metastatic melanoma in 2007, revealed that the drug may prolong survival in melanoma patients. The average overall survival for patients in Phase 1 study was 23.9 months.

The company also announced its plan to compare the efficacy of ImmunoPulse IL-12 with that of Merck & Cos Keytruda in Phase 2b trial [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&biSbc8S8cjN5t5koeXmEQ ].

This is great news for the small company [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&biSbc8S8cjN5t5koeXmEQ ], OncoSec, because the drug, if approved by the FDA, may rake in higher profits from the highly lucrative cancer market.

Global Industry [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=MqG8urofVrjpPYd.0DnzUA ] Analysts Inc. estimated that the worldwide cancer therapy market will reach $225 billion by the year 2017, marking an increase of 147% when compared to the industry`s size in FY13. Andrew Baum, analyst at Citigroup predicted that immunotherapy can bring in $35 billion in revenue by 2023.

OncoSec`s drug can face competition from Merck & Co. Incs (NYSE:MRK [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=MgZPWEXxYTQrMjkNmQDpSQ ]) Keytruda and Bristol-Myers Squibbs (NYSE:BMY [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=tqUccAMg8tF0JYmx15NBaA ]) Yervoy. ImmunoPulse IL-12, however, can beat these competitors if it is successful in establishing its supremacy over Mercks Keytruda in its Phase 2btrial [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=MqG8urofVrjpPYd.0DnzUA ].

Keytruda, in its Phase 2 trial results announced last month, had clearly established its efficacy over Yervoy in treating patients with advanced melanoma. Therefore if OnsoSecs drug proves it is better than Keytruda in Phase 2b trial, it will also establish its efficacy over Yervoy by default.

I`ll talk to you soon! Stockpalooza.com Team Never invest in a stock mentioned by StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] unless you can afford to lose your entire investment.

Release of Liability: Through use of this website viewing or using you agree to holdStockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=VQ6hodz5S51zzVOWHuAXUg ], its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ]`s statements regarding a company.

StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ]`s officers and directors do not own any shares of the mentioned company(s). When StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] receives free or restric ted trading shares as a compensation for a profiled company, StockPalooza.com .com may sell part or all of such shares during the period in which StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] is performing such services. StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company.StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=HgnrNusFmQ01WH33CZCH8w ] has been compensated Ten Thousand Dollars Cash via Bank Wire Transfer by a third party for a 1 Day Marketing Program regarding ONCS. This compensation/expected compensation, expired or not, is a major conflict of interest in our ability to be unbiased.

Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates may wish to liquidate shares, which has the potential to hurt share prices . Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the t imeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. StockPalooza.com.comencourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ] makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. StockPalooza.com.com [ http://clicks.aweber.com/y/ct/l=9tgYk&m=3lkxpDNgbKlix9X&b=8cAneHuX0QRwaAHZguDixw ], nor any of its affiliates are not registered investment. Stockpalooza`s emails and alerts are intended for novelty purposes only.

11020 Vanowen St No. Hollywood CA 91605 We trade for profits! 11020 Vanowen St No. Hollywood CA 91605 To

This entry was posted in Stock Newsletters and tagged , , . Bookmark the permalink.

Comments are closed.